TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Diffuse large B-cell lymphoma (DLBCL) (de novo or DLBCL transformed from follicular lymphoma on the basis of a tissue biopsy).~* Received at least one prior therapy for aggressive Non-Hodgkin's Lymphoma (NHL) (DLBCL).~* Received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) + rituximab or equivalent regimen.~* Patients must have measurable disease.~* Not eligible or not willing to receive the high-dose (myeloablative) chemotherapy (HDC) and stem cell transplant (SCT).~* A fresh tumor biopsy collected during screening and /or archival tumor tissue collected after the last relapse/disease progression.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.~* Left ventricular ejection fraction (LVEF) ≥ the lower limit of normal (LLN) for the Institution. (as per local standard of care) as measured by echocardiogram (ECHO) or Multiple gated acquisition (MUGA) scan.~* Adequate bone marrow, liver and renal function.~Exclusion Criteria:~* Any of the following as the only site(s) of disease: palpable lymph nodes not visible on imaging studies, skin lesions, or bone marrow involvement only.~* Active CTCAE (Common Terminology Criteria for Adverse Events) Grade 3/4 infection.~* Current central nervous system (CNS) involvement by lymphoma.~* Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction within the past 6 months before start of study treatment.~* Uncontrolled arterial hypertension despite optimal medical management (per investigator's opinion).~* Type I or II diabetes mellitus with HbA1c \> 8.5% at Screening.~* New York Heart Association (NYHA) class III or IV heart disease.~* History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator).~* Patients who previously received therapy with copanlisib or other PI3K inhibitors are not eligible for enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copanlisib (Aliqopa, BAY80-6946) (Type: EXPERIMENTAL): Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:~  * Primary refractory disease (no complete response \[CR\] after ≥ 2 induction therapies)~ * Relapsed disease not in CR after ≥ 1 course of standard reinduction therapy~ * Secondary AML from myelodysplastic syndromes~ * Disease relapsed ≥ 2 months after transplant and no option of donor lymphocyte infusions (e.g., recipients of autologous or umbilical cord blood transplants)~ * Chronic myelogenous leukemia with myeloid blast crisis not in second chronic phase after at least one cycle of standard chemotherapy and imatinib~ * Over 60 years of age with relapse within 6 months after completion of last chemotherapy~ * Over 60 years of age with blast count \< 30% within 10 days before study entry~* Related HLA-haploidentical natural killer cell donor available~* No severe organ damage (by clinical or laboratory assessment)~* Performance status 50-100%~* No evidence of active infection on chest X-ray~* No active fungal infection~Exclusion Criteria:~* Active central nervous system (CNS) leukemia~* Pleural effusions large enough to be detectable by chest x-ray~* Pregnant or nursing (positive pregnancy test)~* Fertile patients must use effective contraception~* Less than 60 days since prior transplant~* Less than 3 days since prior prednisone~* Less than 3 days since other prior immunosuppressive medication

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intent-to-Treat (Type: EXPERIMENTAL): All patients treated with natural killer (NK) cells (at a dose of 1.5-8 x 10\^7/kg.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-Patients diagnosed with Hand, foot, and mouth disease~Exclusion Criteria:~* Patients whose complaints lasted more than 48 hours~* Unable to comply with follow-ups,~* Did not give informed consent,~* Another antiviral or supportive treatment,~* Use antibiotics in the previous 1 month,~* A history of immunodeficiency or a family history of immunodeficiency,~* A previous history of anaphylaxis with any supplement or drug,~* Any chronic disease, or skin lesion -

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- EPs® 7630 group (Type: ACTIVE_COMPARATOR): The patients were divided into two groups: (i) group 1 received herbal drug EPs® 7630 by oral route \[Umca® solution; (3x10 drops; between 1-5 years of age, 3x20 drops; 6-12 years of age, 3x30 drops for children \>12 years of age)\] for 7 days.
- control grup (Type: NO_INTERVENTION): Control group did not receive any herbal medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pre-menopausal female between 18 and 48 years of age.~2. E2, P, LH and FSH concentrations within 0.5x of the lower limits of normal range and 2x of the upper limits of normal upper limits of normal range (ULN)~3. Regular menstrual periods for the 3 months prior to study enrollment~4. Body weight ≥ 45 killograms (kgs) and body mass index (BMI) of 20 to 36~5. Capable of giving written informed consent~Exclusion Criteria:~1. Pregnancy~2. Lactating Females~3. Any contraindication to the treatment with E2 and NETA~4. Use of the following medications in the 3 months prior to screening: injectable hormonal contraceptives, sex hormone medications or danazol~5. Use of the following medications in the 6 months prior to screening: injectable gonadotropin-releasing hormone agonists, hormonal, or non-hormonal intrauterine devices~6. History of sensitivity to any of the study medications of components thereof or history of drug~7. Significant gynecological, endocrine, metabolic or other health conditions~8. History of regular alcohol consumption within 6 months of study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Relugolix (Type: EXPERIMENTAL): Participants received relugolix 40 milligrams (mg) alone for 6 weeks.
- Relugolix + E2/NETA (Type: EXPERIMENTAL): Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Convenience Study- NIS RELATE

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Cohort A:~1. A. Written informed consent prior to participation~2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.~3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.~4. A. Patients switched to Pradaxa® according Summary of Product Characteristics and physician's discretion.~OR~Cohort B:~1. B. Written informed consent prior to participation.~2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).~3. B. Stroke prevention treatment initiated with Pradaxa® or VKA according to Summary of Product Characteristics and physician's discretion.~Exclusion criteria:~1. Contraindication to the use of Pradaxa® or VKA as described in the Summary of Product Characteristics (SmPC).~2. Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in atrial fibrillation.~3. Current participation in any clinical trial of a drug or device.~4. Current participation in an European registry on the use of oral anticoagulation in AF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch Patients / A (Type: None): Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
- New Patients / B (Type: None): Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are competent to provide written consent~* Aged 35 to 80 years~* Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg~* All other subjects must have a mean systolic blood pressure ≥140 mmHg~* Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic~* Female subjects of non-childbearing potential (i.e., post-menopausal for at lest 2 years; surgically sterile)~Exclusion Criteria:~* Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg~* Serum ALT or AST \>2 x the upper limit of the normal range (ULN)~* Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (CVA) within 6 month; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia~* Implanted pacemakers or implanted cardioverter defibrillator (ICD)~* Symptomatic congestive heart failure requiring treatment~* Hemodynamically significant valvular heart disease~* Type I diabetes mellitus~* Hemodialysis or peritoneal dialysis; or history of renal transplant~* Diagnosis or recurrence of malignancy within the past 3 years~* Sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation greater than or equal to 90%~* Subjects who perform alternating shift or night work~* Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Darusentan Placebo (Type: PLACEBO_COMPARATOR): Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
- Darusentan 50 mg (Type: EXPERIMENTAL): Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
- Darusentan 100 mg (Type: EXPERIMENTAL): Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
- Darusentan 300 mg (Type: EXPERIMENTAL): Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HBsAg+~* Anti-HBs negative~* HBV titer \> 1x10\^7 copies / ml~* Treatment naïve~* HIV / HCV / hepatitis delta virus negative~* Fibrosis with compensation (as determined by Fibroscan and liver enzymes)~* Non cirrhotic~* No known active cytomegalovirus infection~* Willingness to utilize adequate contraception while being treated with REP 9AC' and for 6 months following the end of treatment~* Adequate venous access allowing weekly intravenous therapies and blood tests~Exclusion Criteria:~* Evidence of cardiovascular disease~* Autoimmune hepatitis~* Presence of Wilson's disease~* Presence of severe NAFLD~* Evidence of any other co-existent liver disease~* Anti-nuclear antibody positive~* Evidence of liver cirrhosis~* A history of ascites, hepatic encephalopathy or variceal hemorrhage~* Body weight \> 100 kg~* Platelet count \< 75,000, polymorphonuclear cell count \< 1,500 or hematocrit \< 33%~* Alpha feto protein \> 100 ng/ml or the presence of a hepatic mass suggestive of hepatocellular carcinoma .~* Bilirubin \> 2.5 mg/dl~* Creatinine \> 1.5 mg/dl~* Platelet count \< 75,000 / cmm~* Serum albumin \< 35 mg/ml~* Poorly controlled diabetes mellitus~* Another serious medical disorder~* A serious psychiatric disorder~* Uncontrolled hypertension~* A history of alcohol abuse within the last year~* The use of illicit drugs within the past two years~* Inability to provide informed consent~* Positive pregnancy test~* Breastfeeding~* Inability or unwillingness to provide weekly blood samples~* Poor venous access making IV infusion too difficult

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- REP 2139-Ca + immunotherapy (Type: EXPERIMENTAL): REP 2139-Ca is the calcium chelate complex formulation of REP 2139.~Zadaxin is thymosin alpha 1~Pegasys is pegylated interferon alpha 2a~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is \> 2000 copies / ml.~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rotigotine Restless Legs Syndrome Dose Finding Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic Restless Leg Syndrome~* Subject has responded previously, according to medical history information, to L-Dopa therapy and/or treatment with a dopamine agonist, if pre-treated~Exclusion Criteria:~* Secondary restless legs syndrome due to, e.g., renal insufficiency (uremia), iron deficiency anemia, rheumatoid arthritis.~* Secondary restless legs syndrome associated with previous or concomitant therapy with dopamine D2 receptor antagonists, butyrophenones, metoclopramid, atypical antipsychotics (e.g., olanzapine), tri- and tetracyclic antide-pressants, mianserine, lithium or H2-blockers (e.g., cimetidine), or due to withdrawal from drugs such as anticonvulsants, benzodiazepines, barbitur-ates, and other hypnotics.~* History of sleep disturbances like sleep apnea syndrome, narcolepsy, myoclonus epilepsy observed during polysomnography (PSG) or explored in subject history.~* Clinically relevant cardiac dysfunction and/or arrhythmias (e.g., suspected conduction system dysregulations, second or third degree AV block, complete left or right bundle branch block, sick-sinus-syndrome, congestive heart failure Class III or IV by NYHA, myocardial infarction within twelve months prior to enrollment).~* Clinically relevant renal dysfunction (serum creatinine \>2.0 mg/dl)~* Clinically relevant hepatic dysfunction (total bilirubin \>2.0 mg/dl or ALT and/or AST greater than two times the upper limit of the reference range).~* QTc-interval in resting ECG \> 450 msec in males and \> 470 msec in females.~* History of symptomatic orthostatic hypotension within 28 days prior to screening visit (Visit 1), or a systolic blood pressure (SBP) less than 105mmHg at trial entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Known diagnosis of polycythemia vera.~2. Hematocrit \>48% before dosing.~3. Evidence of hematocrit \>48% three or more times in the 28 weeks before dosing or five or more times in 52 weeks before dosing (except for newly diagnosed patients).~4. Clinically reasonable alternative causes for erythrocytosis have been evaluated and excluded.~5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.~Exclusion Criteria:~1. Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) within 3 months of Screening.~2. Active or chronic bleeding within 4 weeks of Screening.~3. Meets the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).~4. Infection requiring hospitalization or intravenous antimicrobial therapy, or opportunistic infection within 3 months of dosing; any infection requiring systemic antimicrobial therapy within 4 weeks of dosing. Prophylactic antibiotics are allowed.~5. Any serious or unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject from properly providing informed consent or any condition which would jeopardize compliance with the study.~6. Known primary or secondary immunodeficiency.~7. Known positive for active hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.~8. Any surgical procedure requiring general anesthesia within 1 month prior to Screening or planned elective surgery during the study.~9. History of invasive malignancies within the last 2 years, except non-melanoma skin cancer and localized curatively treated prostate cancer or cervical cancer.~10. Current or recent history of alcohol dependence or illicit drug use within 1 year prior to Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PTG-300 (Type: EXPERIMENTAL): Evaluate PTG-300's efficacy and safety in subjects with PV and baseline elevated hematocrit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of risk factors for venous thromboembolism~* Any parity~* Mode of delivery:vaginal, Emergency and Elective Caesarean section~* No any contraindications for Heparin~Exclusion Criteria:~* Active antenatal or postpartum vaginal bleeding.~* Placenta previa~* Thrombocytopenia~* Sever renal or liver diseases~* Uncontrolled sever hypertension~* Any patient who is already on Heparin during pregnancy

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 48 Years
- Healthy Volunteers: f

Study Arms:
- Bemiparin (Type: ACTIVE_COMPARATOR): A new second generation Low Molecular Weight Heparin
- Enoxaparin (Type: ACTIVE_COMPARATOR): A well known Low Molecular Weight Heparin
- control group (Type: NO_INTERVENTION): Risky group patients for VTE, but they will not receive any thromboprophylactic drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete